Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.
Further Study Information
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined. Trial with medicinal productEligibility Criteria
Inclusion criteria:
Hemodialyis patients with at least one case of in-situ or invasive squamous cell carcinoma of the skin
Exclusion criteria:
Hepatopathy
Hepatopathy
Pregnancy
No comments:
Post a Comment